Biohaven pharmaceutical holding company ltd. (BHVN)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-639,438

-528,805

-434,291

-389,565

-217,764

-240,922

-213,254

-194,728

-193,899

-127,190

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash share-based compensation expense

64,521

54,972

39,342

33,113

21,167

16,925

14,872

17,386

14,441

13,239

0

0

0

Non-cash interest expense on mandatorily redeemable preferred shares

18,272

12,711

0

0

0

-

-

-

-

-

-

-

-

Non-cash interest expense on liability related to sale of future royalties

28,188

26,580

24,864

23,189

18,543

11,726

0

0

0

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

-

784

0

0

0

Change in fair value of derivative liability

9,656

3,875

0

0

0

-

-

-

-

-512

0

0

0

Change in fair value of warrant liability

-

-

-

-

-

1,182

-1,086

1,340

3,969

3,241

0

0

0

Change in fair value of contingent equity liability

-

-

-

-

-

-

-

-

-

13,082

0

0

0

Loss from equity method investment

-6,556

-6,076

-5,050

-3,754

-2,980

-2,808

-2,747

-2,688

-2,395

-1,885

0

0

0

Other non-cash items

-989

-646

-615

-487

-385

-269

-105

-101

-85

-64

0

0

0

Changes in operating assets and liabilities:
Trade receivables, net

0

-

-

-

0

-

-

-

-

-

-

-

-

Inventories

0

-

-

-

0

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

27,321

3,464

-8,199

-1,537

-501

2,893

11,046

5,847

9,520

4,730

0

0

0

Other assets

183

232

287

-19

8

-21

0

0

0

-

-

-

-

Accounts payable

20,336

3,319

6,263

8,201

-1,376

5,390

-4,066

10

5,543

3,975

0

0

0

Accrued expenses and other current liabilities

39,479

43,320

25,038

22,439

10,425

3,697

-3,509

1,287

-1,677

1,341

0

0

0

Other long-term liabilities

61

-1,975

-2,052

-1,380

-1,410

576

595

-21

10

29

0

0

0

Net cash used in operating activities

-481,184

-377,331

-310,300

-288,908

-162,477

-197,141

-204,492

-177,102

-168,696

-94,815

0

0

0

Purchases of property and equipment

2,512

2,534

3,168

4,112

4,846

4,165

2,922

1,993

877

541

0

0

0

Purchase of equity method investment

-

-

-

-

-

6,375

5,003

5,003

6,378

6,627

0

0

0

Payments for leasehold improvements

0

-

-

-

0

-

-

-

-

-

-

-

-

Payments for intangible assets

0

-

-

-

0

-

-

-

-

-

-

-

-

Net cash used in investing activities

-26,112

-3,784

-8,168

-9,112

-9,846

-10,540

-7,925

-6,996

-7,255

-7,168

0

0

0

Proceeds from issuance of common shares

586,554

303,221

438,346

417,125

135,125

190,125

0

0

0

-

-

-

-

Payments of issuance costs

1,490

1,150

0

0

0

-

-

-

-

5,068

0

0

0

Proceeds from issuance of Series A preferred shares

-

-

-

-

-

-

-

-

-

-

0

0

0

Proceeds from exercise of stock options

7,066

5,524

3,663

2,701

3,386

3,324

0

0

0

-

-

-

-

Net cash provided by financing activities

719,128

434,593

567,857

546,307

285,524

340,462

204,848

197,260

227,811

209,759

0

0

0

Net increase in cash and restricted cash

211,832

53,478

249,389

248,287

113,201

132,781

-7,569

13,162

51,860

107,776

0

0

0

Supplemental disclosure of cash flow information:
Cash paid for interest

0

0

0

0

0

0

0

24

97

122

0

0

0

Cash paid for income taxes

415

823

895

738

661

333

0

0

0

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities:
Deferred offering costs included in accounts payable

0

-

0

0

0

-

0

0

0

-

0

0

0

Intangible asset costs included in accounts payable

0

-

-

-

0

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

0

Beneficial conversion feature on Series A preferred shares

-

-

-

-

-

-

-

-

-

-12,006

0

0

0

Accretion of beneficial conversion feature on Series A preferred shares

-

-

-

-

-

-

-

-

-

12,006

0

0

0

Issuance of Series A preferred shares as payment of offering costs

-

-

-

-

-

-

-

-

-

1,242

0

0

0

Issuance of common shares as payment of equity investment

-

-

-

-

-

-

-

-

-

352

0

0

0